fashion -WSS

fashion

author：fashion 2025-08-28 08:40:28 - browse：613

Anthony Fernandez holds a Wegovy injection, the ALP-1 agonist medication he uses to help curb his food cravings – Obesity medication and science coverage for STAT — A person holds a Wegovy injection pen. Kayana Szymczak for STAT

Medicare confirmed this week that it will cover Novo Nordisk’s obesity drug Wegovy if prescribed to prevent heart problems, but policy experts said Medicare patients are still likely to encounter significant barriers getting access to the highly popular and expensive drug.

Medicare previously wasn’t reimbursing for Wegovy, since the federal payer is legally barred from covering weight loss drugs. But the Food and Drug Administration this month approved Wegovy for preventing heart problems in people with obesity and heart disease, leading many to suspect that Medicare would start covering the drug for this usage.

Makers of obesity drugs have been hoping that showing additional benefits beyond weight loss would induce more insurers to cover them. Medicare’s guidance, first reported Thursday, moves in that direction, but experts point out that the private insurers that administer Medicare’s prescription drug benefit — called Part D — can still choose to not include Wegovy on their formularies, especially if they think it would be too costly.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hollywood unions extend contract negotiations for actors
Next article： How doctors’ personal politics affect patients

WSS

Being 'nonadherent' patient made me a more empathetic doctor

Being 'nonadherent' patient made me a more empathetic doctor

CDC Director Mandy Cohen on transparency, trust, and health

Prescription digital therapeutics are key to pharma’s future

AstraZeneca lung cancer study comes in below expectations

AstraZeneca lung cancer study comes in below expectations

hotspot

fashion

explore

Dobbs anniversary: the lost opportunity of abortion as health care

Top Ukrainian generals say counteroffensive is 'going to plan' as losses mount

Alkermes shareholders re

What to watch for from Zogenix and Amicus clinical trials

United colonoscopy coverage change 'may cost lives,' doctors say

The battle over 'scope creep' and who gets to be called 'doctor'

Tori Bowie and the unacceptable rates of Black maternal death

A new crop of companies is reshaping the health data economy

Alkermes shareholders re

Vertex cell therapy lets patients with type 1 diabetes stop insulin

focus

A new crop of companies is reshaping the health data economy

STAT wants to know your pick for a great summer read or listen

Archived: an online chat discussing Ebola, vaccines, and a new epidemic

In the gardens at Boston Children's Hospital, families find sanctuary

The biotech scorecard for Q3: 15 stock

Correcting Robert F. Kennedy Jr.'s vaccine 'facts'

hotspot

entertainment

focus

focus